drugset / Trial / NCT03405831
Effect of Ivabradine on Exercise Capacity After Heart Transplantation
Phase 4
Unknown
35 enrolled
Finn Gustafsson
Danish Heart Foundation · collabRigshospitalet, Denmark · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates whether treatment with ivabradine compared to placebo can improve exercise capacity in long-term heart transplant recipients with cardiac allograft vasculopathy and elevated heart rate at rest. Patients will receive treatment with either ivabradin or placebo for a period of 12 weeks.
Timeline
- Start
- 2018-04-17
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ivabradine | Small molecule | 5 mg | Oral |
Indications
No indication recorded.